Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications. Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, C...